Ketamine: From medicine to misuse

CNS Drugs

Volumn 20, Issue 3, 2006, Pages 199-218

  Wolff, Kim ^a   Winstock, Adam R ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SYDNEY SOUTH WEST AREA HEALTH SERVICE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; ALFENTANIL; ANESTHETIC AGENT; BENZODIAZEPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUNITRAZEPAM; GLUTAMATE RECEPTOR; GLUTAMIC ACID; HALOPERIDOL; HYPNOTIC AGENT; IMALGEN; KETAMINE; KETAMINE 500; KETANEST; KETOPROFEN; LAMOTRIGINE; LORAZEPAM; LYSERGIDE; METHADONE; MIDAZOLAM; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALOXONE; OLANZAPINE; OXYBATE SODIUM; PHENCYCLIDINE DERIVATIVE; PSYCHEDELIC AGENT; RISPERIDONE; SEDATIVE AGENT;

ABNORMAL SENSATION; ALCOHOLISM; ALERTNESS; AMNESIA; ANALGESIA; ANESTHETIC RECOVERY; ANXIETY; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUDITORY HALLUCINATION; BLUNTED AFFECT; BLURRED VISION; BONE MARROW BIOPSY; CANCER PAIN; CARDIOVASCULAR EFFECT; CATALEPSY; COGNITION; COGNITIVE DEFECT; DELIRIUM; DELUSIONAL DISORDER; DEPERSONALIZATION; DISORIENTATION; DISSOCIATIVE AMNESIA; DISSOCIATIVE DISORDER; DREAMING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG OVERDOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERANCE; EMOTIONAL DISORDER; EPILEPTIC STATE; EUPHORIA; EYE DISEASE; FORENSIC MEDICINE; GAS CHROMATOGRAPHY; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART PALPITATION; HEROIN DEPENDENCE; HUMAN; IMAGERY; INJURY; INSOMNIA; INTENSIVE CARE UNIT; LONG TERM EXPOSURE; LONG TERM POTENTIATION; MAJOR DEPRESSION; MEMORY DISORDER; MENTAL INSTABILITY; MIGRAINE; MOOD CHANGE; MUSCULOSKELETAL DISEASE; NEGATIVE SYNDROME; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PARALYSIS; PARANOIA; PERCEPTION DISORDER; PERSEVERATION; PERSONALITY DISORDER; POSITIVE SYNDROME; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOTHERAPY; RECALL; RECEPTOR BLOCKING; RECOGNITION; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEDATION; SENSORY DEPRIVATION; SEXUAL CRIME; SIDE EFFECT; SLURRED SPEECH; SPEECH DISORDER; TACHYCARDIA; THORAX PAIN; THOUGHT DISORDER; VERBAL MEMORY; VISUAL DISORDER; VIVID DREAM; WITHDRAWAL SYNDROME;

ANESTHETICS, DISSOCIATIVE; ANIMALS; HUMANS; KETAMINE; SUBSTANCE-RELATED DISORDERS;

EID: 33644897612     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620030-00003     Document Type: Review

References (177)

1. Ashton H, Young MD. Drug induced psychiatric disorders. In: Davies DM, Ferrner CFR, Glenville DE, editors. Davies' textbook of adverse drug reactions. UK: Chapman Hall Medical Publications, 1998: 669-731
2. White PF, Way WL, Trevor AJ. Ketamine: its pharmacology and therapeutic uses. Anaesthesiology 1982; 56: 1
3. Stafford P. Contrasting profiles. In: Stafford P, editors. Psychedelics encyclopedia. 3rd ed. Berkeley (CA): Ronin Pub Inc., 1991: 392-5
4. Domino EF, Chodoff P, Corssen G. Pharmacologic effects of C1-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 1965; 6 (3): 279-86
5. Adams HA, Wener C. From the racemate to the enantiomers (S) ketamine: renaissance of a substance? Anaesthesia 1997; 46: 1026-42
6. Jansen KLR. Ketamine (K) and quantum psychiatry. Asylum 1999; 11 (3): 19-21
7. Lilly JC. The scientist: a novel autobiography. New York: JB Lippincott, 1978
8. Grinspoon L, Bakalar JB. The major psychedelic drugs. In: Grinspoon L, Bakalar JB, editors. Sources and effects. New York: Basic Books Inc. Pub, 1981: 32-6
9. Jevtovic-Todorovic V, Todorovic SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med 1998; 4: 460-3
10. Krystal JH, Petrakis IL, Webb E, et al. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry 1998; 55 (4): 354-60
11. Ghonheim MM, Hinrichs JV, Mewaldt SP, et al. Ketamine: behavioural effects of subanaesthetic doses. J Clin Psychopharmacol 1985; 5: 70-7
12. Green SM, Sherwin TS. Incidence and severity of recovery agitation after ketamine sedation in young adults. Amer J Emerg Med 2005; 23: 142-4
13. Erowid ketamine vault: dose, chemistry and basics [online]. Available from URL: http://www.erowid.org/chemical/ketamine/ketamine-dose.shtml [Accessed 2005 Dec 12]
14. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anesth 1989; 36 (2): 186-97
15. Elsohy MA, Flee L, Holzhauer LB, Salamone SJ. Analysis of urine samples in cases of alleged sexual assault. Case History. In: Salamone SJ, editor. Benzodrazepines and GHB: detection and pharmcology. Forensic Science and Medicine Series. Totowa, (NJ): Humana Press Inc., 2001: 127-44
16. Krystal JH, Karper LP, Seibyl JP, et al. Subanaesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51 (3): 199-214
17. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 16: 120-5
18. Baer G, Parkas P. Ketamine-induced psychopathological changes in normal volunteers during conditions used for experimental psychoses (author's transl). Anaesthesist 1981; 30 (5): 251-6
19. Newcomber JW, Farber NB, Jevtovic-Todorovic V, et al. Ketamine induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999; 20: 106-18
20. Green SM, Johnson NE. Ketamine sedation for pediatric procedures: part 2, review and implications. Ann Emerg Med 1990; 19: 1033-46
21. Hetem LA, Danion JM, Diemunsch P, et al. Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology 2001; 22: 59-72
22. Hansen G, Jenson SB, Chandresh L, et al. The psychotropic effect of ketamine. J Psychoactive Drugs 1988; 20 (4): 419-25
23. Curran HV, Morgan C. Cognitive dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 2000; 95 (4): 575-90
24. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role on N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1992; 260: 1209-13
25. Curran HV, Monaghan L. In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 2001 96; 5: 749-60
26. Wolff K, Hay AW, Sherlock K, et al. Contents of ecstasy. Lancet 1996; 346: 1100-1
27. Winstock AR, Griffiths P, Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001; 64 (1): 9-17
28. Wood PL. The NMDA receptor complex: a long and winding road to therapeutics. IDrugs 2005; 8: 229-35
29. Kong PE, Snijdelaar DG, Crug BJ. Parental administration of low dose ketamine for the treatment of neuropathic pain in cancer patients. Ned Tijdschr Geneeskd 2002; 146: 2556-8
30. Nishimura N, Sato K. Ketamine stereoselectively inhibits rat dopamine transporter. Neurosci Lett 1999 Oct 22; 274 (2): 131-4
31. Rowland LM, Bustillo JR, Mullins PG, et al. Effects of ketamine on anterior cingulated glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 2005; 162 (2): 394-6
32. Nishimura N, Sato K, Okada T, et al. Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 1998; 88: 768-74
33. Fagg GE. Phencyclidine and related drugs bind to the activated NMDA receptor chanel complex in rat brain membranes. Neurosci Lett 1987; 76: 221-9
34. Anis NA, Berry SC, Burton NR, et al. The dissociative anaesthetics ketamine and phencyclidine selectively reduce excitation of central mammalian neurons by N-methyl-D-aspartate. Br J Pharmacol 1983; 79: 565-75
35. Gao KM, Saku K, Roberts RC, et al. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus; effects of schizophrenia. Am J Psychiatry 2000; 157: 1141-9
36. Harrison PJ, Law AJ, Eastwood SL. Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann N Y Acad Sci 2003; 1003: 94-101
37. Morris RGM, Anderson E, Lynch GS, et al. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist. AP5. Nature 1986; 319: 774-6
38. Lynch G, Baudry M. The biochemistry of memory: a new and specific hypothesis. Science 1984; 224: 1057-63
39. Cotman CW, Monaghan DT. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Ann Rev Neurosci 1988; 11: 60-80
40. Honey RA, Turner DC, Honey GD, et al. Subdissociative doses of ketamine produces a deficity in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology 2003; 28: 2037-44
41. Chambers RA, Bremner JD, Moghaddam B, et al. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin Clin Neuropsychiatry 1999; 4 (4): 274-81
42. Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57 (3): 270-6
43. Moghaddam B, Adams B, Verma A, et al. Activation of glutaminergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to doperminergic and cognitive disruptions associations with the prefrontal cortex. J Neurosci 1997; 17: 2921-7
44. Hirota K, Okawa H, Appadu BL, et al. Sterioselective interaction of ketamine with recombinant mu, kappa and delta opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology 1999; 90: 174-82
45. Mikkelsen S, Ilkjaer S, Brennum J. The effect of naloxone on ketamine-induced effects on hyperalgesia and ketamine-induced side effects in humans. Anesthesiology 1999; 90: 1539-45
46. Gorman AL, Elliot KJ, Inturrisi CE. The d -and l -isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in forebrain and spinal cord. Neurosci Lett 1997; 223: 5-8
47. Kissin I, Bright CA, Bradley Jr EL. The effect of ketamine on opioid-induced acute tolerance: can it explain reduction of opioid consumption with ketamine-opioid analgesic combinations? Anaesth Analg 2000; 91 (6): 1483-8
48. Byrd LD, Standish LJ, Howell LL. Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs. Eur J Pharmacol 1987 Dec 15; 144 (3): 331-41
49. Kienbaum P, Heuter T, Pavlakovic G, et al. S (+)-Ketamine increases muscle sympathetic activity and maintains the neural response to hypotensive challenges in humans. Anesthesiology 2001; 94 (2): 252-8
50. Adams HA, Thiel A, Jung A, et al. Effects of S- (=)-ketamine on the endocrine and cardiovascular parameters: recovery and psychomimetic reactions in volunteers. Anaesthesist 1992; 41: 558-96
51. Doenicke A, Kugler J, Mayer M, et al. Influence of racemic ketamine and S- (+) -ketamine on vigilance, performance and wellbeing. Anaesthestist 1992; 41: 610-8
52. Adams AH. [S-(+) ketamine: circulatory interactions during total intravenous anaesthesia and analgesia sedation. Anaesthetists 1997; 46: 1081-7
53. Engelhardt W. Recovery and psychic emergence reactions after S- (+)-ketmaine. Anaesthesist 1997; 46 Suppl. 1: 538-42
54. Vollenweider FX, Leenders KL, Oye I, et al. Differential psychopathology and patterns of cerebral glucose utilization produced by (S)- and (R) -ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 1997; 7: 25-38
55. Mathisen LC, Skjelbred P, Skoglund LA, et al. Effect of ketamine, and NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain 1995; 2694: 1-6
56. Matthews KS, Toner CC, McLaughlin DP, et al. Comparison of ketamine sterioisomers on tissue metabolic activity in an in vitro model of global cerebral ischemia. Neurochem Int 2001; 38: 367-72
57. Zeilhofer HU, Swandulla D, Geisslinger G, et al. Differential effects of ketamine enantiomeres on NMDA receptor currents in cultured neurons. Eur J Pharmacol 1992; 213: 155-8
58. Duncan GE, Leipzig JN, Mailman RB, et al. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 1998; 812 (1-2): 65-75
59. Oye I, Hustveit O, Maurset A, et al. The chiral forms of ketamine as probes for NMDA-receptor function in humans. In: Kameyama T, Nabeshima T, Domino EF, editors. NMDA receptor related agents: biochemistry, pharmacology and behavior. Ann Arbor (MI): NPP Books, 1991: 381-9
60. Durieux ME, Nietgen GW. Synergistic inhibition of muscarinic signaling by ketamine stereoisomers and the preservative benzethonium chloride. Anesthesiology 1997 Jun; 86 (6): 1326-33
61. Klepstad P, Maurset A, Moberg ER, et al. Evidence of a role for NMDA receptors in pain perception. Eur J Pharmacol 1990 Oct 23; 187 (3): 513-8
62. Jansen KLR. Ketamine, dreams and realities. Florida: Multi disciplinary Association for Psychedelic Studies, 2000
63. Marhofer P, Freitag H, Hochtl A, et al. S (+)-Ketamine for rectal premedication in children. Anesth Analg 2001; 92 (1): 62-5
64. Azevedo VM, Lauretti GR, Pereira NL, et al. Transdermal ketamine as an adjuvant for post operative analgesia after abdominal gynecological surgery using lidocaine epidural blockade. Anesth Analg 2000; 91 (6): 1479-82
65. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992; 13: 77-185
66. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002; 7: 853-8
67. Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2001; 6: 887-90
68. Huang MK, Liu C, Li JH, et al. Quantitative detection of ketamine, norketmaine and dehydronorketamine in urine using chemical derivatization followed by gas chormatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 820: 165-73
69. Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of MI and oral ketamine. Br J Anaesth 1981; 53: 805-10
70. Kronenberg RH. Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration. J Pain Palliat Care Pharmacother 2002; 16: 27-35
71. Amiot JF, Roessler JG, Amadea B, et al. Anaesthesia with oral ketamine. Cati Anaesthesiol 1987; 35: 203-5
72. Jantzen JP, Erdmann K, Hilley D, et al. Comparative study of analgesia and plasma level following rectal, intramuscular and intravenous administration of ketamine. Anaesthesist 1985; 34: 346-51
73. Siegel RK. Phencyclidine and ketamine intoxication: a study of four populations of recreational users. In: Peterson RC, Stillman RC, editors. Phencyclidine abuse: an appraisal. Rockville (MD): National Institute on Drug Abuse, 1978
74. Yanagihara Y, Ohtani M, Kariya S, et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 2003; 24: 37-43
75. Huang GS, Yeh CC, Kong SS, et al. Intra-articular ketamine for pain control following arthroscopic knee surgery. Acta Anaesthesiol 2000; 152 (3): 283-8
76. Ahmed SN, Petchkovsky L. Abuse of ketamine. Br J Psychiatry 1980; 137: 303
77. Cottingham R, Thomson K. Use of ketamine in prolonged entrapment. J Accid Emerg Med 1994; 11 (3): 189-91
78. Bishop RA, Litch JA, Stanton JM. Ketamine anesthesia at high altitude. High Alt Med Biol 2000; 1 (2): 111-4
79. Paix BR, Capps R, Neumeister G, et al. Anaesthesia in a disaster zone: a report on the experience of an Australian medical team in Banda Aceh following 'Boxing Day Tsunami'. Anaesth Intensive Care 2005; 33: 629-34
80. Kaube H, Herzog J, Kaufer T, et al. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000; 55 (1): 139-41
81. Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res 2000; 42 (2-3): 117-22
82. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47 (4): 351-4
83. Lloyd-Williams M. Ketamine for cancer pain. J Pain Symptom Manage 2000; 19 (2): 79-80
84. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 2003; 97: 1730-9
85. Bennett JA, Bullimore JA. The use of ketamine hydrochloride anaesthesia for radiotherapy in young children. Br J Anaesth 1973; 45: 197-9
86. Khorramzadeh E, Lofty AO. The use of ketamine in psychiatry. Psychosomatics 1973; 14: 344-6
87. Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs 1997; 29 (2): 165-83
88. Sivolap IP, Savchenkov VA. Experience in using ketamine preparations in the psychotherapy of alcoholism. Zh Nevropatol Psikhiatr Im S S Korsakova 1994; 94 (4): 76-9
89. Krupitsky E, Burakov A, Romanova T, et al. Ketamine psychotherapy for heroin-addiction: immediate effects and two-year follow-up. J Subst Abuse Treat 2002; 4: 273-83
90. Bush M, Grobler DG, Raath JP, et al. Use of medetomidine and ketamine for immobilization of free-ranging giraffes. J Am Vet Med Assoc 2001; 218 (2): 245-9
91. Vercruysse Jr J, Mortelmans J. The chemical restraint of apes and monkeys by means of phencyclidine or ketamine. Acta Zool Pathol Antverp 1978; 70: 211-20
92. Sing V, Kinjavadekar P, Aithal HP, et al. Medetomidine with ketamine and bupivacaine for epidural analgesia in buffaloes. Vet Res Commun 2005; 29: 1-18
93. Adler CM, Malhotra AK, Elman I, et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999; 156 (10): 1646-9
94. Abi-Saab WM, D'Souza DC, Moghaddam B, et al. The NMDA-antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 1998; 31: 104-9
95. Carpenter WT. The schizophrenia ketamine challenge study debate. Biol Psychiatry 1999; 46 (8): 1081-91
96. Tamminga C. Glutamatergic aspects of schizophrenia. Br J Psychiatry Suppl 1999; (37): 12-5
97. Vollenweider FX, Vontobel P, Oye I, et al. Effects of (S)-ketamine on striatal dopamine: a [11C] raclopride PET study of a model psychosis in humans. J Psychiatr Res 2000; 34 (1): 35-43
98. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20 (3): 201-2
99. Lahti AC, Koffel B, LaPorte D, et al. Subanaesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13 (1): 9-19
100. Smith GS, Schloesser R, Brodie JD, et al. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11-raclopride in normal human subjects. Neuropsychopharmacology 1998; 18: 18-25
101. Duncan GE, Miyamoto S, Lieberman A. Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation. J Pharmacol Exp Ther 2003; 305: 999-1005
102. Trujillo KA. The effects of non-competetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacology 1995; 13 (4): 301-7
103. Narita M, Kato H, Miyoshi K, et al. Treatment for psychological dependence on morphine: usefulness of hinhibiting NMDA receptor and its associated protein kinase in the nucleus accumbens. Life Sci 2005; 16: 2207-20
104. Ji D, Sui ZY, Ma YY, et al. NMDA receptor in nucleus accumbens is implicated in morphine withdrawal in rats. Neurochem Res 2004; 29: 2113-20
105. Rothman SM, Thurston JB, Hauhart RE, et al. Ketamine protects hippocampal neurons from anoxia in vitro. Neuroscience 1987; 21: 673-8
106. Meldrum B. Possible therapeutic applications for antagonists of excitatory amino acid neurotransmitters. Clin Sci 1985; 68: 113-22
107. Sonsalla PK, Nicklas WJ, Heikkila RE. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 1989; 243 (4889): 398-400
108. Lahti AC, Warfel D, Michaelidis T, et al. Long-term outcome of patients who receive ketamine during research. Biol Psychiatry 2001; 49: 869-75
109. Hersack RA. Ketamine's psychological effects do not contraindicate its use based on a patient's occupation. Aviat Space Environ Med 1994; 65: 1041-6
110. Ishihara H, Kudo H, Murakawa T, et al. Uneventful total intravenous anaesthesia with ketamine for schizophrenic surgical patients. Eur J Anaesthesiol 1997; 14: 47-51
111. Lahti AC, Warfel D, Michaelidis T, et al. Outcome of patients who receive ketamine. Biol Psychiatry 2001; 49: 869-75
112. Kelly K. The little book of ketamine. Berkeley (CA): Ronin Publishing Co., 1999
113. Dillon P, Copeland J, Jansen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend 2003; 69: 23-8
114. Dotson JW, Ackerman DL, West LJ. Ketamine abuse. J Drug Issues 1995; 25: 751-7
115. Zinberg NE. The basis for controlled intoxicant use. New Haven/London: Yale University Press, 1984
116. Jansen KL. Non medical use of ketamine. BMJ 1993; 306 (6878): 601-2
117. RELEASE. RELEASE drugs and dance survey: an insight into the culture. London: RELEASE, 1997 (Contact: RELEASE, 388 Old Street, London EC1V 9LT, UK)
118. Skovmand K. Swedes alarmed at ketamine misuse [letter]. Lancet 1996; 348 (9020): 122
119. White JM, Ryan CF. Pharmacological properties of ketamine. Drug Alcohol Rev 1996; 15 (2): 145-55
120. Ompad DC, Galea S, Fuller CM, et al. Club drug use among minority substance users in New York City. J Psychoactive Drugs 2004; 36: 397-9
121. Lankenau SE, Clatts MC. Patterns of polydrug use amont ketamine injectors in New York City. Subst Use Misuse 2005; 40: 1381-97
122. Dalgarno PJ, Shewan D. Illicit use of ketamine in Scotland. J Psychoactive Drugs 1996; 28 (2): 191-9
123. Bohr N. On atoms and human knowledge. Daedalus 1958; 87 (2): 53-61
124. Winstock AR, Wolff K, Ramsey J. Pill testing: harm minimisation gone too far? Addiction 2001; 96: 1130-48
125. Shapiro H. Ketamine factsheet. London: Institute for the Study of Drug Dependence (ISDD), 1991
126. Gough N. Ketamine: China's other white powder [online]. Available from URL: http: //www.time.com/time/asia/covers/1101020520/ketamine.html [Accessed 2005 Apr 15]
127. Arditti J, Spadari M, DeHaro L, et al. Ketamine: dreams and realities. Acta Clin Belg Suppl 2002; 1: 31-3
128. Tori SP. Ketamine Abuse "Special K". Middle Atlantic-Great Lakes Organized Crime Law Enforcement Network (MAGLO-CLEN). Bethesda (MD): NDIC Publications, 1996
129. Gable RS. Acute toxic effects of club drugs. J Psychoactive Drugs 2004; 36: 303-13
130. Topp L, Hando J, Degenhardt L, et al. Ecstasy use in Australia. Monograph number 39. Sydney: National Drug and Alcohol Research Centre, 1998
131. Topp L, Breen C, Kaye S, et al. NSW party drug trends 2001: findings from the Illicit Drug Reporting System (IDRS). Technical report number 136. National Drug and Alcohol Research Centre, Sydney
132. Drug Enforcement Agency. Ketamine abuse increasing (1997) [online]. Available from URL: http://www.usdoj.gov/dea/program/diversion/div/pub/ substance/ketamine.htm [Accessed 2005 Dec 12]
133. Jansen KL. A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs 2000 Oct-Dec; 32 (4): 419-33
134. Parks KA, Kennedy CL. Club drugs: reasons for consequences of use. J Psychoactive Drugs 2004; 36: 295-302
135. Leary T, Sirius RU. Design for dying. London: Thorsons/Harper Collins, 1997
136. Weiner AL, Vieria L, McKay CA, et al. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 2000; 18: 447-51
137. US Department of Health and Human Services and SAMSHA National Cleaning House for Information. Ketamine: a factsheet [online]. Available from URL: http://www.health.org/nongovpubs/ketamine [Accessed 2005 Dec 9]
138. Anglin D, Spears KL, Hutson HR. Flunitrazepam and its involvement in date or acquaintance rape. J Accid Emerg Med 1997; 4: 323-6
139. Merle R. "Special-K" is latest US drug fad. The Seattle Times, 1997 Jun 20
140. Bolze S, Boulieu R. HPLC determination of ketamine, norketamine and dehydronorketamine in plasma with a high purity reversed phase sorbent. Clin Chem 1998; 44: 560-4
141. Chen LL, Liao LC, Wang ZL. Determination of ketamine and its metabolites in biological samples [in Chinese]. Fa Yi Zue Za Zhi 2005; 21: S5-7
142. Adamowicz P, Kala M. Urinary excretion rates of ketamine and norketamine following therapeutic ketamine administration: method and detection window considerations. J Anal Toxicol 2005; 29: 376-82
143. Shannon M. Recent ketamine administration can produce a urine toxic screen which is falsely positive for phencyclidine [letter]. Pediatr Emerg Care 1998; 14: 180
144. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
145. Bowdle TA, Radant AD, Cowley DS, et al. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anaesthesiology 1998; 88: 82-8
146. Matsuki A, Ishihara H, Kotani N, et al. A clinical study of total instravenous anesthesia by using mainly propofol, fentanyl and ketamine: with special reference to its safety based on 26, 079 cases. Masui 2002; 51: 1336-42
147. Lalonde BR, Wallage HR. Postmortem blood ketamine distribution in two fatalities. J Anal Toxicol 2004; 28: 71-4
148. Breitmeier D, Mansouri F, Albrecht K, et al. Accidental autoerotic deaths between 1978 and 1997. Forensic Sci Int 2003; 137: 41-4
149. Murphy Jr JL. Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse. Can J Anaesth 1993; 40: 160-4
150. Felser JM, Orban DJ. Dystonic reaction after ketamine abuse. Ann Emerg Med 1982; 11 (12): 673-5
151. Green SM, Clark R, Hostetler MA, et al. Inadvertent ketamine overdose in children: clinical manifestations and outcome. Ann Emerg Med 2005; 34: 492-7
152. Gill JR, Stajic M. Ketamine in non-hospital and hospital deaths in New York City. J Forensic Sci 2000; 45 (3): 655-8
153. Beardsley PM, Balster RL. Behavioral dependence upon phencyclidine and ketamine in the rat. J Pharmacol Exp Ther 1987; 242 (1): 203-112
154. Johnstone RE. A ketamine trip [letter]. Anesthesiology 1973; 39: 460-1
155. Albin M, Dresner J, Paolin A, et al. Long-term personality evaluation in patients subjected to ketamine hydrochloride and other anaesthetic agents. Pharmacology: Abstracts of Scientific Papers p166. American Society of Anesthesiologists Annual Meeting; 1970
156. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-30
157. Malhotra AK, Pinals DA, Caleb MA, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17: 141-50
158. Klein M, Calderon S, Hayes B. Abuse liability assessment of neuro-protectants. Ann N Y Acad Sci 1999; 890: 515-2
159. Lahti AC, Holcomb HH, Gao XM, et al. NMDA-sensitive glutamate antagonism: a human model for psychosis. Neuropsychopharmacology 1999; 21: S158-69
160. Melkonian DL, Meshcheriakov AV. Possibility of predicting and preventing psychotic disorders during ketamine anesthesia. Anesteziol Reanimatol 1989; 3: 15-8
161. Steen PA, Michenfelder JD. Neurotoxicity of anesthetics. Anesthesiology 1979; 50: 437-53
162. Schorn TO, Whitwam JG. Are there long term affects of ketamine on the central nervous system? Br J Anaesth 1980; 52 (10): p967-8
163. Adler CM, Goldbert TE, Malhotra AU, et al. Effects of ketamine on thought disorder, working memory and semantic memory in healthy volunteers. Biol Psychiatry 1998; 43: 811-6
164. Gardner EL. Brain reward mechanisms. In: Lowinson H, Ruiz P, Millman RB, et al., editors. Substance abuse: a comprehensive textbook. 3rd ed. Baltimore (MD): Williams and Wilkins, 1996: 51-85
165. Jansen KL. Ketamine: can chronic use impair memory? Int J Addict 1990; 25 (2): 133-9
166. Pal HR, Berry N, Kumar R, et al. Ketamine dependence. Anaesth Intensive Care 2002; 30: 382-4
167. Kamaya H, Krishna PR Ketamine addiction. Anesthesiology 1987; 67 (5): 861-2
168. Hurt PH, Ritchie EC. A case of ketamine dependence [letter]. Am J Psychiatry 1994; 151 (5): 779
169. Moore NN, Bostwick JM. Ketamine dependence in anesthesia providers. Psychosomatics 1999; 40 (4): 356-9
170. Jansen KLR, Darracot-Cankovic R. The non medical use of ketamine, part two: a review of problem use and dependence. J Psychoactive Drugs 2001; 33: 151-8
171. Leccese AP, Marquis KL, Mattia A, et al. The anticonvulsant and behavioral effects of phencyclidine and ketamine following chronic treatment in rats. Behav Brain Res 1986; 22: 257-64
172. Benthuysen JL, Hance AJ, Quam DD, et al. Comparison of isomers of ketamine on catalepsy in the rat and electrical activity of the brain and behavior in the cat. Neuropharmacology 1989; 28: 1003-9
173. Byer DE, Gould AB. Development of tolerance to ketamine in an infant undergoing repeated anesthesia. Anesthesiology 1981; 54: 225-56
174. Collier BB. Long term dangers of ketamine anesthesia [letter]. Br J Anaesth 1981; 53: 552
175. MacLennen FM. Ketamine tolerance and hallucinations in children [letter]. Anaesthesia 1928; 37: 1214-25
176. Klepstad P, Borchgrevink PC. Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia. Acta Anaesthesiol Scand 1997; 41: 422-6
177. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 1986; 97: 1730-9